Your browser doesn't support javascript.
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
FitzGerald, Richard; Dickinson, Laura; Else, Laura; Fletcher, Thomas; Hale, Colin; Amara, Alieu; Walker, Lauren; Penchala, Sujan Dilly; Lyon, Rebecca; Shaw, Victoria; Greenhalf, William; Bullock, Katie; Lavelle-Langham, Lara; Reynolds, Helen; Painter, Wendy; Holman, Wayne; Ewings, Sean; Griffiths, Gareth; Khoo, Saye.
  • FitzGerald R; National Institute for Health Research Royal Liverpool & Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom.
  • Dickinson L; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Else L; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Fletcher T; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
  • Hale C; National Institute for Health Research Royal Liverpool & Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom.
  • Amara A; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Walker L; National Institute for Health Research Royal Liverpool & Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom.
  • Penchala SD; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Lyon R; National Institute for Health Research Royal Liverpool & Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom.
  • Shaw V; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Greenhalf W; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Bullock K; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Lavelle-Langham L; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Reynolds H; Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, United Kingdom.
  • Painter W; Ridgeback Biotherapeutics, Miami, Florida, USA.
  • Holman W; Ridgeback Biotherapeutics, Miami, Florida, USA.
  • Ewings S; National Institute for Health Research Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
  • Griffiths G; National Institute for Health Research Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
  • Khoo S; National Institute for Health Research Royal Liverpool & Broadgreen Clinical Research Facility, Liverpool University Hospital NHS Foundation Trust, Liverpool, United Kingdom.
Clin Infect Dis ; 75(1): e525-e528, 2022 08 24.
Article in English | MEDLINE | ID: covidwho-1852997
ABSTRACT
ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and nasal NHC were significantly correlated with plasma (P < .0001). Clinical Trials Registration. NCT04746183.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prodrugs / COVID-19 Drug Treatment Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prodrugs / COVID-19 Drug Treatment Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid